Angela A. Armstrong

Array ( [id] => 16519479 [patent_doc_number] => 10870689 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-22 [patent_title] => ApoM-Fc fusion proteins, complexes thereof with sphingosine 1-phosphate (S1P), and methods for treating vascular and non-vascular diseases [patent_app_type] => utility [patent_app_number] => 16/326089 [patent_app_country] => US [patent_app_date] => 2017-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 14073 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16326089 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12058638 [patent_doc_number] => 20170334982 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-23 [patent_title] => 'Inflammatory Disease Treatment Composition Including Anti-Myosin Regulatory Light-Chain Polypeptide Antibody' [patent_app_type] => utility [patent_app_number] => 15/667644 [patent_app_country] => US [patent_app_date] => 2017-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 14206 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15667644 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15355627 [patent_doc_number] => 10526414 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-01-07 [patent_title] => Use of anti-semaphorin-4D antibodies in combination with an immune modulating therapy to inhibit tumor growth and metastases [patent_app_type] => utility [patent_app_number] => 15/666133 [patent_app_country] => US [patent_app_date] => 2017-08-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 43 [patent_figures_cnt] => 43 [patent_no_of_words] => 29959 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 116 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15666133 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12118828 [patent_doc_number] => 20180002413 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-04 [patent_title] => 'INFLAMMATORY DISEASE DIAGNOSIS AND METHODS OF TREATMENT USING LIPOPOLYSACCHARIDE-RESPONSIVE BEIGE-LIKE ANCHOR' [patent_app_type] => utility [patent_app_number] => 15/661784 [patent_app_country] => US [patent_app_date] => 2017-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 82 [patent_figures_cnt] => 82 [patent_no_of_words] => 45860 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15661784 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14169277 [patent_doc_number] => 10258625 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-04-16 [patent_title] => Method for treatment of metastatic and refractory cancers and tumors with an inducer that overcomes inhibition of T cell proliferation [patent_app_type] => utility [patent_app_number] => 15/661100 [patent_app_country] => US [patent_app_date] => 2017-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 61 [patent_no_of_words] => 14702 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 139 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15661100 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17095426 [patent_doc_number] => 20210283217 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-09-16 [patent_title] => NEUROMODULATING COMPOSITIONS AND RELATED THERAPEUTIC METHODS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES [patent_app_type] => utility [patent_app_number] => 16/320321 [patent_app_country] => US [patent_app_date] => 2017-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 79667 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -104 [patent_words_short_claim] => 26 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16320321 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13699989 [patent_doc_number] => 20170360949 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-12-21 [patent_title] => POLYPEPTIDE COMPLEX AS POLYPEPTIDE OR PROTEIN DRUG CARRIER, METHOD OF USING THE POLYPEPTIDE COMPLEX, AND FUSION PROTEIN COMPLEX THEREOF [patent_app_type] => utility [patent_app_number] => 15/658419 [patent_app_country] => US [patent_app_date] => 2017-07-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15791 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15658419 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14306391 [patent_doc_number] => 20190142899 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-16 [patent_title] => TREATMENT OF ISCHEMIA REPERFUSION INJURY USING ALPHA-2 MACROGLOBULIN [patent_app_type] => utility [patent_app_number] => 16/315684 [patent_app_country] => US [patent_app_date] => 2017-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4841 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16315684 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12030854 [patent_doc_number] => 20170320952 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-09 [patent_title] => 'METHODS OF TREATING CANCER WITH ANTIBODIES THAT TARGET THE INSULIN-LIKE GROWTH FACTOR TYPE I RECEPTOR (IGF-1R)' [patent_app_type] => utility [patent_app_number] => 15/646813 [patent_app_country] => US [patent_app_date] => 2017-07-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 26 [patent_no_of_words] => 30754 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15646813 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15385621 [patent_doc_number] => 10533988 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-01-14 [patent_title] => Methods for treating central or peripheral nervous system damage [patent_app_type] => utility [patent_app_number] => 15/644450 [patent_app_country] => US [patent_app_date] => 2017-07-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 15 [patent_figures_cnt] => 45 [patent_no_of_words] => 21455 [patent_no_of_claims] => 18 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 104 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15644450 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16335571 [patent_doc_number] => 10786509 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-09-29 [patent_title] => Treatment and prevention of atherothrombosis by inhibition of bruton's tyrosine kinase (BTK) [patent_app_type] => utility [patent_app_number] => 16/314370 [patent_app_country] => US [patent_app_date] => 2017-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 19 [patent_no_of_words] => 15493 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16314370 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12023964 [patent_doc_number] => 20170314063 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-02 [patent_title] => 'TIE2 RECEPTOR ACTIVATION FOR GLAUCOMA' [patent_app_type] => utility [patent_app_number] => 15/631806 [patent_app_country] => US [patent_app_date] => 2017-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 6676 [patent_no_of_claims] => 12 [patent_no_of_ind_claims] => 11 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15631806 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12746512 [patent_doc_number] => 20180140671 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-05-24 [patent_title] => COMPOSITIONS AND METHODS FOR CARDIAC TISSUE REPAIR [patent_app_type] => utility [patent_app_number] => 15/623025 [patent_app_country] => US [patent_app_date] => 2017-06-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16389 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -7 [patent_words_short_claim] => 17 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15623025 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18887714 [patent_doc_number] => 11866475 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-09 [patent_title] => Modified RNA encoding VEGF-A polypeptides, formulations, and uses relating thereto [patent_app_type] => utility [patent_app_number] => 16/305224 [patent_app_country] => US [patent_app_date] => 2017-06-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 53 [patent_figures_cnt] => 82 [patent_no_of_words] => 36656 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 32 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16305224 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16443716 [patent_doc_number] => 10835620 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-11-17 [patent_title] => Methods for treating heart failure using beta-ARKnt peptide [patent_app_type] => utility [patent_app_number] => 16/306718 [patent_app_country] => US [patent_app_date] => 2017-06-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 54 [patent_figures_cnt] => 123 [patent_no_of_words] => 20466 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16306718 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11971223 [patent_doc_number] => 20170275378 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-28 [patent_title] => 'MONOCLONAL ANTIBODY, INHIBITING THE ENZYMATIC ACTIVITY OF VASCULAR ENDOTHELIAL LIPASE' [patent_app_type] => utility [patent_app_number] => 15/611864 [patent_app_country] => US [patent_app_date] => 2017-06-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 25 [patent_figures_cnt] => 25 [patent_no_of_words] => 18446 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15611864 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12118842 [patent_doc_number] => 20180002428 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-01-04 [patent_title] => 'ANTI-CXCR4 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES' [patent_app_type] => utility [patent_app_number] => 15/610417 [patent_app_country] => US [patent_app_date] => 2017-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 64153 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15610417 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14945791 [patent_doc_number] => 10434141 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-10-08 [patent_title] => Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody [patent_app_type] => utility [patent_app_number] => 15/610527 [patent_app_country] => US [patent_app_date] => 2017-05-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 62 [patent_no_of_words] => 40130 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15610527 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12060080 [patent_doc_number] => 20170336425 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-23 [patent_title] => 'PIP2 AS A MARKER FOR HDL FUNCTION AND CARDIOVASCULAR DISEASE RISK' [patent_app_type] => utility [patent_app_number] => 15/598522 [patent_app_country] => US [patent_app_date] => 2017-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 17 [patent_no_of_words] => 10707 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15598522 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12975301 [patent_doc_number] => 20170340515 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-11-30 [patent_title] => PHARMACEUTICAL COMPOSITIONS COMPRISING HUMAN ANTIBODIES TO PCSK9 [patent_app_type] => utility [patent_app_number] => 15/595373 [patent_app_country] => US [patent_app_date] => 2017-05-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 63782 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15595373 [rel_patent_id] =>[rel_patent_doc_number] =>)